论文部分内容阅读
方法 :用ACS :180化学发光分析仪测定 2 12例糖类抗原CA19 9。目的 :探讨CA19 9在消化系统恶性肿瘤与良性疾病中的临床意义及价值。结果 :恶性病组血清CA19 9分别与正常组相比差异非常显著 (P <0 .0 0 1) ,良性病组血清CA19 9分别与正常组相比无差异 (P >0 .1) ,恶性病组血清CA19 9分别与良性病组相比差异显著 (P <0 .0 5 )。结论 :血清CA19 9含量测定胰腺癌的阳性率 87.9% ,肠癌阳性率 60 .5 % ,肝癌阳性率 5 9.6% ,胃癌阳性率 44 .7% ,说明CA19 9含量测定对诊断胰腺癌和肠癌具有特异性的临床价值。并且提示CA19 9测定可作为鉴别胃癌与慢性胃炎 ,肝癌与慢性肝炎的实验参考指标。
Methods: Two hundred and twenty-two carbohydrate antigens CA19 9 were determined by ACS: 180 chemiluminescence analyzer. Objective: To investigate the clinical significance and value of CA19 9 in digestive system malignancies and benign diseases. Results: Serum CA19 9 in malignant group was significantly higher than that in normal group (P <0.01). There was no difference in serum CA19 9 between benign group and normal group (P> 0.01) Serum CA19 9 in patients with benign disease compared with the significant difference (P <0. 05). Conclusion: The positive rate of serum CA19 9 in pancreatic cancer was 87.9%, the positive rate of intestinal cancer was 60.5%, the positive rate of liver cancer was 59.6%, and the positive rate of gastric cancer was 44.7%. It indicated that the determination of CA19 9 in pancreatic cancer and intestine Cancer has a specific clinical value. And prompted CA19 9 determination can be used as a differential diagnosis of gastric cancer and chronic gastritis, liver cancer and chronic hepatitis experimental reference index.